ReviewHeart failure reviews2025
Echocardiographic monitoring in cancer therapy: clinical guidance for cardiologists and oncologists.
Review in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular Imaging for the Early Detection of Cardiotoxicity from Emerging Cancer Therapies: Mechanistic Insights Across the Pediatric and Adult Spectrum.Journal of personalized medicine · 2026Review
- Diagnostics in cardio-oncology: a focus on anthracyclines.Heart failure reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthoracic echocardiography has a central role in the diagnosis and monitoring of cancer therapy-related cardiac dysfunction, offering a reliable, non-invasive, and cost-effective tool for the early detection of myocardial damage and the timely and effective management of cardiotoxicity. This review provides a practical and comprehensive framework for the echocardiographic assessment of oncology patients, focusing on both traditional and emerging ultrasound parameters of left and right ventricular function, and their diagnostic and prognostic value in the field of cardio-oncology. Moreover, the review discusses key aspects of pericardial disease, valvular heart disease, and intracardiac masses, which may be consequences of cancer therapy or tumor progression. Finally, the role of multimodal imaging, in particular cardiac magnetic resonance and computed tomography, is examined, especially in selected cases to supplement echocardiographic findings or when echocardiography presents limitations. Based on current guidelines and clinical experience, this review aims to provide both cardiologists and oncologists with a practical tool for interpreting echocardiographic reports in cancer patients. Additionally, a therapeutic algorithm is proposed to guide decisions on cancer treatment management and timely initiation of cardioprotective strategies in selected contexts. Close collaboration between cardiologists and oncologists remains essential to reduce cancer patients' cardiovascular risk, allowing them to access the best possible treatment and optimize outcomes by balancing anticancer therapy efficacy with cardiovascular safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.